Literature DB >> 19965954

A comparison of culture-positive and culture-negative health-care-associated pneumonia.

Andrew J Labelle1, Heather Arnold, Richard M Reichley, Scott T Micek, Marin H Kollef.   

Abstract

OBJECTIVE: The aim of this study is to describe the initial antibiotic treatment regimens, severity of illness, and in-hospital mortality among culture-negative (CN) and culture-positive (CP) patients with health-care-associated pneumonia (HCAP).
METHODS: We used a retrospective cohort study, examining adult patients with HCAP from Barnes-Jewish Hospital, a 1,200-bed urban teaching hospital.
RESULTS: Eight hundred seventy patients with HCAP were identified over a 3-year period (January 2003 through December 2005) of whom 431 (49.5%) were CP. Among the non-CP patients, 290 (66.1%) had no respiratory cultures obtained, and 149 (33.9%) had no growth or nonpathogenic oral flora identified and were classified as CN. CN patients were more likely to have received an initial antibiotic regimen (ceftriaxone +/- azithromycin or moxifloxacin) targeting community-acquired pneumonia pathogens compared with CP patients (71.8% vs 25.5%, P < .001). Severity of illness as assessed by ICU admission and mechanical ventilation (MV) was statistically lower in CN compared with CP patients (ICU admittance 12.1% vs 48.7%, P < .001; MV: 6.7% vs 44.5%, P < .001). In-hospital mortality and hospital length of stay were also statistically lower for CN patients (mortality: 7.4% vs 24.6%, P < .001; hospital length of stay: 6.7 +/- 7.4 days vs 12.1 +/- 11.7 days, P < .001).
CONCLUSIONS: In this analysis, patients with CN HCAP had lower severity of illness, hospital mortality, and hospital length of stay compared with CP patients. These data suggest that patients with CN HCAP differ substantially from patients with HCAP with positive microbiologic cultures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965954     DOI: 10.1378/chest.09-1652

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

Review 1.  The Lung Microbiome and Its Role in Pneumonia.

Authors:  Benjamin G Wu; Leopoldo N Segal
Journal:  Clin Chest Med       Date:  2018-12       Impact factor: 2.878

Review 2.  Update in pulmonary infections 2010.

Authors:  Richard G Wunderink; Grant W Waterer
Journal:  Am J Respir Crit Care Med       Date:  2011-07-15       Impact factor: 21.405

3.  Examination with next-generation sequencing technology of the bacterial microbiota in bronchoalveolar lavage samples after traumatic injury.

Authors:  Ryan M Huebinger; Ming-Mei Liu; Scot E Dowd; Fernando A Rivera-Chavez; John Boynton; Curtis Carey; Kenneth Hawkins; Christian T Minshall; Steven E Wolf; Joseph P Minei; Robert C Barber
Journal:  Surg Infect (Larchmt)       Date:  2013-05-06       Impact factor: 2.150

4.  Guideline-based antibiotics and mortality in healthcare-associated pneumonia.

Authors:  Karl J Madaras-Kelly; Richard E Remington; Kevin L Sloan; Vincent S Fan
Journal:  J Gen Intern Med       Date:  2012-03-07       Impact factor: 5.128

5.  Development of an antibiotic spectrum score based on veterans affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach.

Authors:  Karl Madaras-Kelly; Makoto Jones; Richard Remington; Nicole Hill; Benedikt Huttner; Matthew Samore
Journal:  Infect Control Hosp Epidemiol       Date:  2014-07-25       Impact factor: 3.254

6.  Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study.

Authors:  Marco Falcone; Salvatore Corrao; Giuseppe Licata; Pietro Serra; Mario Venditti
Journal:  Intern Emerg Med       Date:  2012-06-12       Impact factor: 3.397

7.  One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System.

Authors:  Joe L Hsu; Andrew M Siroka; Mark W Smith; Mark Holodniy; G Umberto Meduri
Journal:  Int J Infect Dis       Date:  2011-03-09       Impact factor: 3.623

8.  A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia.

Authors:  John M Boyce; Olivia-Fabiola Pop; Odaliz Abreu-Lanfranco; Whitney Y Hung; Ann Fisher; Afshin Karjoo; Benjamin Thompson; Zenon Protopapas
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

9.  Antimicrobial de-escalation of treatment for healthcare-associated pneumonia within the Veterans Healthcare Administration.

Authors:  Karl Madaras-Kelly; Makoto Jones; Richard Remington; Christina M Caplinger; Benedikt Huttner; Barbara Jones; Matthew Samore
Journal:  J Antimicrob Chemother       Date:  2015-11-03       Impact factor: 5.790

10.  JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.

Authors:  Keiichi Mikasa; Nobuki Aoki; Yosuke Aoki; Shuichi Abe; Satoshi Iwata; Kazunobu Ouchi; Kei Kasahara; Junichi Kadota; Naoki Kishida; Osamu Kobayashi; Hiroshi Sakata; Masahumi Seki; Hiroki Tsukada; Yutaka Tokue; Fukumi Nakamura-Uchiyama; Futoshi Higa; Koichi Maeda; Katsunori Yanagihara; Koichiro Yoshida
Journal:  J Infect Chemother       Date:  2016-06-15       Impact factor: 2.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.